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De8pite,recunt8dvwcwinthethelapyofp8tiultswitllhe8rt 
5ilm, a substantial wnberofpatieW still have consider- 
able disabiity aad a markedly shorMwl ife span. Thus, a 
greatlEedBnddiGMrewediesrennains. 
Thegenesisafanoveltherapeuticeatityisadau& 
procesB,lequM@EcomndtrmdafcoasidaaMe 
TbcGmt#epIathisplwe~isthe~to~-~ 
newdNgtaQet8onthebnsisofthelateat~dii. 
RapidideiWMmofaleulcba&alsbwtme,modi6edas 
lleededtoobtainthede!dredpotencyand~cbar- 
~,isakey&vItynecwsuyforswces&ldtqg 
dew&mmLllle!#elecM~-thcn~ 
ligonus~co- tlleabswceof- 
aaimaltoxidcy.subssqueatly,trialSh~~~to 
docummttheeelcacyand!J&!tyafthenewchemiadeatity.It 
iSimpel&vethBttlEriSk/beWfltI&tilWfthedWgbe&Ily 
&llaed. 
RegWoryappwalisobtaMana~ofl2yeamafter 
syntlAs of a sew &emical entity (1). For every 1QJKNl 
che&alenti&ssyr&&ed,10enterllmmtrialsancl1~ 
Eaia~llclproval(l).~higblevelafliBkiavolvedin 
l-nwxuw~aad~is~~ 
thesteepwitddeve&&aaewmedia&m.Ibecurrent 
e&ateofthecosttothe~iudushyforeacb 
Pmdact@iaiqJ~approvali8$231 million(l). 
EeartFaihuwPubKcEedthBurtlen 
HeartlXlureisagrowiagpublichealthproblem.Inthe 
Uaited~,iti8estimatadthat~2millionpsaplebave 
ympUlU&heWtlhilUlEandthat4ooOlNlneWcaSeS~ 
&osedyearly(2~.ThemunberofcaAofheartGlureis 
expected to increase further as survival fter ante myocar- 
diiialWioaincnasesandthepopul&nages.Inthe 
Framin&m Heart Study (2). the prevalence of heart failure 
inuea!A progres&ely with age, ill- from 0.8% ill 
per8oasbetweeaSOand59yearsofageto9.1%inpersoas 
betweenIaad89yearsdage.Heert~~isalsotbemost 
common diagaostic-felated group repoHed inthe elderly. 
Them&rityofpatWswithheartf&retreatedbyphy- 
&iawueca&@wLdasha*mildto-disease; 
!#vemhealtfailunacwlmts~aboutl5%oftlletreated 
patientpoplwoa(3).Depeadiqgootbe~yoftheir 
diSN,a!lIWlm#rtalitynteslWlgefnwnlO%MO%iIl 
~wirh_he3ute3ut (2,4S). nuril& t!!e course oftheir 
experience c..* my, 
which&e&ctediathehi&~oencyofhoqitaladmissions 
awio&edwithtidii.Acconliagtodatafionathe 
centefsforDiseasecoatrol,~forhealtfeilure 
illtheuaited~tripledbetweeatheeiiulyl97osand 
mid-l980s,~ayewlytatalofapprorrimatelyl~miUioa 
dmiagthelatlerpefiod.Healt~~theleading 
CXUlSe~hO6piM-illtheeldetIy(165yelUSof~~. 
Illtllisgroupofpatiarts,ithasalsobeenidentifiedastbemost 
canmanreasonlXrWmiGontothehospital(6).Medicwe 
stawc!Srevealtheextentdthe eamamicbmdelltothe 
aat&inl989tbeaverageha#alstayforp&atswithheart 
lhilurewaa8da~a1ulcostS4,373(ii~~ 
per hoqital stay avenging $715). 
Tbus,heart4irilunisal&WeaWdagdiso&raad, 
duringthecomseofthedisease,patientsareexposedto 
umsidemble morbidity. There is unquestionable ne d for 
additional&rapeu&iaterveationstoimpnwethebleak 
outlook for patients with heart Glare. 
CnrrentplrssidrurMiU~ 
HeartFailare 
Taerapeuticappn&esavaiWe~pa&ntswithheart 
fArearediscussedel8ewhereilltbissupplemeat.These 
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Ftgurel. Physicians’~oftheiruscofdipitnlir,angiotcllsin- 
comedog enzyme inhiitors (ACEIs) and dimztic dqs for the 
katmentofmiId,moderatezmdsevemheartGhn-e.CD=cmdiob 
&as; GPRP = garal pmctitionef5 or blily practitioners: IM = 
iluemal medicine speciaIists. lnlrcfz: consumer Mustlial Research 
Service, November 1991. 
therapeutic strategies m effected predominantly by primary 
care physicians, who account for 78% of clinic visits for 
heart failure; visits to cardiologists represent only 18% of the 
total number of visits (7). 
Physicians were queried recently as to their use of 
digWs, diuretic drugs and an&ten&-converting enzyme 
inhibitors for the treatment of patients with heart failure; the 
results of this survey appear in Fi 1. In general, cardi- 
ologists tated that hey used angiotensin-converting enzyme 
inhibitors more frequently and earlier in the course of the 
disease than did internists and family or general practi- 
tioners. The overwhelming wority of physicians included 
diuretic drugs as part of the therapeutic armamentarium for 
all degrees ofheart failure. The frequent use of diuretic drugs 
was ako documented when prescriptions written for patients 
with heart fkilure were examiued. However, ~20% dhitid 
pre~criptim~, were written for angiotensin-converting en- 
zyme inhibitors (Fig. 2); cardiologists ended to prescribe 
these agents more frecluently thau did primary care physi- 
ChIlS. 
Given the beneficial elects reported aith angiotensin- 
converting enzyme inhiiir8 in patients with heart failure, 
F@re 2. Pcrccnt of initial prescriptions for digita& angioknsin- 
copvertiq enzyme i&ii (ACEIs) and diuretic dn@s wrItten for 
patie~tswitbhemtfailunbyprimarycarepbysiciansOand 
caldi~sts (CD). source: Me, Intenlal Medicine specialists 
(MS), National DiseaseTherapeutk Index. 
TabIe 1. Physician Awareness of the Studies of left vent&&r 
Dysfuncticm (WLVD) 
SGLVD Study Awarewsa 
Total GPm CD 
(n=266, In = 150) (n = so) 
unaided (46) 11 4 32 
- m 36 27 36 
uPware ($1 39 69 32 
Awamcss of ACE Inhibihm in SCILVD 
blmoll8ulmenwarrdsGLVD~ 
Total Gm4 CD 
(n = 81) (n=47) (II = 34) 
Enahpril (4s) 36 26 56 
CmoPd (46) 12 13 12 
unawale ($1 52 62 38 
ACE = aogbiwmm enzyme; CD = cddogist; GP = ~aml 
practitioimlM=intedmedkim~pcctlist;SOLVD=SPldiesofLdt 
Ventricular Function mntment trial. Some: UIR Hat Failure Suvey. 
mober 1991. 
their actual use by preAbiq physicians would be ex- 
pected to be much higher than that reported. The slow 
adoption of highly elkctive new therapeutic apl#oaches 
could have an adverse impact on the public health. This 
issue is particularly relevant for the data obtakd in the 
Studies of Left Ventricular Dysfunction (SOLVD) treatment 
trial (4). the largest and krgest trial involvisg patients with 
heart failure. The results, published in the widely read New 
I3zgkz~d Journal of Medicine in August 1991 (4), demon- 
strated that enalapril-wheo added to conventioaal therapy 
consisting of diuretic drugs, digitalis or m other 
thau angiotensin-convertiqj enxyme inhibW+reduced 
mortaliiand hospitaladmissionsforheartfailureiupatients 
With~tiJ’ddtO-83’lU~he?ut 
hilure. A survey of physicians conducted in October 1991 
revealedthat~wereuaabletorecalltheIreg~tofthe 
trii kittout assistance (Tab!e !). Even with assistance (that 
is, aided) the m+ity (59%) were still unaware ofthe W 
on the SOLVD m trial.Amougphysiciausi5miKar 
withthetrial,<5O%wereabletoidentiQeaa@Wilasthc 
angiotensin-converting enxyme inhibitor used in the study. 
These obserWons emphask the need for targekd issem- 
ination ofimportant therapeutic advances. 
conclusion 
To date, drug development i  heart failure has fd on 
idenMyingagentsthatmodi@thehemodynamicdeFange 
ments present in these seriou8ly illpatients. A great need for 
altermuive drug development strategies exists. However, 
progress in genemt@ innovative Wapeutk approaches 
willbeimpededbytheabseuceofreliableauimalmodels. 
Nevertheless, the inexoraHe downhill clinical course char- 
acteristicofpatient8withheartthihuedemandsv@orous 
pursuit of improved r medk. succe88fld att&ment ofthis 
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